Citi analyst Itay Michaeli upgraded$Tesla (TSLA.US)$to Neutral from Sell with a price target of $176, up from $141.33. The year-to-date pullback in the shares has "balanced out" the near-term risk/reward, Michaeli tells investors in a research note. With Tesla's multiple contracting to 30-times estimated 2023 earnings, some of the "prior baked-in expectations that we didn't agree with are out of the stock," writes the analyst.
Medtronic Downgraded to Neutral From Buy at Citi
Citi analyst Joanne Wuensch downgraded$Medtronic (MDT.US)$to Neutral from Buy with a price target of $85, down from $108, post the fiscal Q2 reuslts. This was one of those quarters when investors question the ability of Medtronic to deliver mid-single-digit revenue growth over time, Wuensch tells investors in a research note.
Prudential Double Downgraded to Market Perform at Raymond James
Raymond James analyst Wilma Burdis downgraded$Prudential Financial (PRU.US)$to Market Perform from Strong Buy without a price target. After meeting with Prudential Chairman and CEO Charles Lowrey, Burdis tells investors in a research note that the company does not believe its path forward is linear, as its diverse businesses have growth opportunities in multiple markets.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.